Clinical trials: Fibrous Dysplasia
Puberty, Precocious, McCune-Albright Syndrome
Faslodex in McCune-Albright Syndrome
The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with…
- Trial name
- FMAS (NCT00278915)
- Testing
- Fulvestrant
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
This study will test the safety and effectiveness of letrozole in treating precocious (early) puberty in girls with McCune-Albright syndrome (MAS).
- Conditions
- McCune Albright Syndrome, Polyostotic Fibrous Dysplasia, Precocious Puberty
- Trial name
- NCT00006174
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Fibrous Dysplasia/McCune-Albright Syndrome
Pain in Fibrous Dysplasia
Pain remains a common and frequently debilitating symptom, particularly during adulthood of Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS).
- Trial name
- NCT04125862
- Testing
- MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Fibrous Dysplasia of Bone
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
This trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.
- Trial name
- PROFIDYS (NCT00445575)
- Testing
- risedronate
- Where
- 8 sites in Belgium, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Fibrous Dysplasia, Albright Syndrome
Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities
PTH secretion defects (grouped under the name hypoparathyroidism) are due to abnormalities in the PTH gene, abnormalities in the development of the parathyroid glands which synthesize PTH or abnormalities of the calcium sening…
- Conditions
- Fibrous Dysplasia, Albright Syndrome, Adult Children, Hypoparathyroidism
- Trial name
- GNAS-AUTAX (NCT04671719)
- Testing
- blood sample
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Hospices Civils de Lyon
Polyostotic Fibrous Dysplasia
Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
This study will investigate how a gene mutation (change in DNA) causes the abnormal bone in fibrous dysplasia-a condition in which areas of normal bone are replaced with a fibrous growth similar to a scar.
- Trial name
- NCT00001973
- Where
- United States
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
McCune-Albright Syndrome
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Polyostotic fibrous dysplasia (PFD) is a sporadic disorder which affects multiple sites in the skeleton. The bone at these sites is rapidly resorbed and replaced by abnormal fibrous tissue or mechanically abnormal bone.
- Trial name
- NCT00001727
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Fibrous Dysplasia, Fibrous Dysplasia of Bone
Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data
Fibrous dysplasia is a benign, pseudotumoral, genetic but non-hereditary condition characterized by the presence of one or more areas of abnormal bone development in which the normal structure is replaced by fibrous tissue.
- Conditions
- Fibrous Dysplasia, Fibrous Dysplasia of Bone, Fibrous Dysplasia/McCune-Albright Syndrome, Mazabraud Syndrome
- Trial name
- FIBR DYSPLASIA (NCT07569731)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Ortopedico Rizzoli
Fibrous Dysplasia of Bone, McCune Albright Syndrome
Effectiveness of Medical Management of Fibrous Dysplasia of Bone.
The objective of our study was to assess the effectiveness of our reference center since its constitution. In a retrospective cohort study, we compared the activity of our center, including the time elapsed between diagnosis and…
- Trial name
- Efficience (NCT05422833)
- Testing
- Evaluation and analysis of clinical data
- Where
- France
- Volunteers
- 528 people
- Sponsor
- Hospices Civils de Lyon
Fibrous Dysplasia, McCune Albright Syndrome
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
The FD/MAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD/MAS by completing questionnaires about their lives with FD or MAS.
- Conditions
- Fibrous Dysplasia, McCune Albright Syndrome, Mazabraud Syndrome
- Trial name
- NCT03231644
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Tovah Burstein
Cherubism
Genetic and Functional Analysis of Cherubism
The goal of this research study is to identify genes and regulatory elements on chromosomes that cause cherubism. Together with the investigators collaborators the investigators also study blood samples and tissue samples from…
- Trial name
- CBM (NCT01630447)
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- UConn Health
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
This study will examine the effect of pegvisomant on growth hormone excess in patients with McCune-Albright syndrome (MAS). Patients with this disease have polyostotic fibrous dysplasia-a condition in which areas of normal bone…
- Trial name
- NCT00017927
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
McCune-Albright Syndrome
Arimidex in McCune Albright Syndrome
The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
- Trial name
- NCT00055302
- Testing
- Arimidex 1 mg
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Craniofacial Fibrous Dysplasia
Treatment Protocol and Long-Term Outcomes in Craniofacial Fibrous Dysplasia
Craniofacial fibrous dysplasia (CFD) is a nonneoplastic disease characterized by fibro-osseous lesions in the affected bones. Treatment is mainly surgical and is stratified based on four different anatomical zones.
- Trial name
- CFD (NCT06167122)
- Testing
- Craniofacial reconstruction
- Where
- Taiwan
- Volunteers
- 13 people
- Sponsor
- Chang Gung Memorial Hospital
Polyostotic Fibrous Dysplasia
Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
This study will evaluate the effectiveness of alendronate in treating the bone abnormality in polyostotic fibrous dysplasia and McCune-Albright syndrome.
- Trial name
- NCT00001728
- Testing
- Fosamax (Alendronate)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
McCune-Albright Syndrome
Histamine Responsiveness in McCune-Albright Syndrome
McCune-Albright syndrome (MAS) is a syndrome caused by a genetic mutation that causes a specific protein in the body called a G protein to be constantly active.
- Trial name
- NCT00318097
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Fibrous Dysplasia
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
Background: Fibrous dysplasia (FD) is a disease that affects the bones. It causes bone lesions that can become weak and lead to fractures, deformity, and nerve injuries.
- Trial name
- NCT05419050
- Testing
- denosumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Polyostotic Fibrous Dysplasia, Precocious Puberty
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
The normal changes of puberty, such as breast enlargement, pubic hair and menstrual periods, usually begin between the ages of 9 and 15 in response to hormones produced in the body.
- Trial name
- NCT00001181
- Testing
- Testolactone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Fibrous Dysplasia Of Bone
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Background: Fibrous dysplasia (FD) is a disorder that affects bone growth. Affected bone tissue is weakened, and people with FD are prone to deformities, fractures, and other problems.
- Trial name
- NCT05509595
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Polyostotic Fibrous Dysplasia
Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
This study will evaluate the effectiveness of a new bone injection technique for treating bone disease in patients with polyostotic fibrous dysplasia or McCune-Albright syndrome.
- Trial name
- NCT00001851
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)